125 related articles for article (PubMed ID: 22562097)
21. Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5.
van Geelen CM; Pennarun B; Le PT; de Vries EG; de Jong S
BMC Cancer; 2011 Jan; 11():39. PubMed ID: 21272366
[TBL] [Abstract][Full Text] [Related]
22. Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: The search for sensitizing agents.
Moxley KM; Chengedza S; Benbrook DM
Gynecol Oncol; 2009 Dec; 115(3):438-42. PubMed ID: 19804900
[TBL] [Abstract][Full Text] [Related]
23. Natural immunity enhances the activity of a DR5 agonistic antibody and carboplatin in the treatment of ovarian cancer.
El-Gazzar A; Perco P; Eckelhart E; Anees M; Sexl V; Mayer B; Liu Y; Mikulits W; Horvat R; Pangerl T; Zheng D; Krainer M
Mol Cancer Ther; 2010 Apr; 9(4):1007-18. PubMed ID: 20371719
[TBL] [Abstract][Full Text] [Related]
24. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
25. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model.
Buchsbaum DJ; Zhou T; Grizzle WE; Oliver PG; Hammond CJ; Zhang S; Carpenter M; LoBuglio AF
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3731-41. PubMed ID: 14506165
[TBL] [Abstract][Full Text] [Related]
26. Cisplatin-mediated c-myc overexpression and cytochrome c (cyt c) release result in the up-regulation of the death receptors DR4 and DR5 and the activation of caspase 3 and caspase 9, likely responsible for the TRAIL-sensitizing effect of cisplatin.
Zhu X; Zhang K; Wang Q; Chen S; Gou Y; Cui Y; Li Q
Med Oncol; 2015 Apr; 32(4):133. PubMed ID: 25796504
[TBL] [Abstract][Full Text] [Related]
27. Salinomycin induces apoptosis via death receptor-5 up-regulation in cisplatin-resistant ovarian cancer cells.
Parajuli B; Shin SJ; Kwon SH; Cha SD; Chung R; Park WJ; Lee HG; Cho CH
Anticancer Res; 2013 Apr; 33(4):1457-62. PubMed ID: 23564786
[TBL] [Abstract][Full Text] [Related]
28. Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation.
Qiao C; Hu M; Guo L; Lv M; Lin Z; Geng J; Lang X; Li X; Li Y; Ma Y; Feng J; Shen B
BMC Immunol; 2012 Jul; 13():40. PubMed ID: 22788777
[TBL] [Abstract][Full Text] [Related]
29. Pro-survival effects by NF-κB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer.
Yang J; Li G; Zhang K
Biomed Pharmacother; 2016 Dec; 84():1078-1087. PubMed ID: 27780136
[TBL] [Abstract][Full Text] [Related]
30. Treatment of small cell lung cancer with TRA-8 in combination with cisplatin and radiation.
Bonner JA; Willey CD; Yang ES; Dobelbower MC; Sanford LL; Bright SJ; Buchsbaum DJ; Raisch KP
Radiother Oncol; 2011 Oct; 101(1):183-9. PubMed ID: 21722984
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of IGF-1R-dependent PI3K activation sensitizes colon cancer cells specifically to DR5-mediated apoptosis but not to rhTRAIL.
Pennarun B; Kleibeuker JH; Oenema T; Stegehuis JH; de Vries EG; de Jong S
Cell Oncol (Dordr); 2011 Jun; 34(3):245-59. PubMed ID: 21538027
[TBL] [Abstract][Full Text] [Related]
32. A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells.
Petrucci E; Pasquini L; Petronelli A; Saulle E; Mariani G; Riccioni R; Biffoni M; Ferretti G; Benedetti-Panici P; Cognetti F; Scambia G; Humphreys R; Peschle C; Testa U
Gynecol Oncol; 2007 May; 105(2):481-92. PubMed ID: 17292950
[TBL] [Abstract][Full Text] [Related]
33. Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade.
Das S; Tripathi N; Preet R; Siddharth S; Nayak A; Bharatam PV; Kundu CN
Oncotarget; 2017 Jan; 8(1):248-267. PubMed ID: 27542249
[TBL] [Abstract][Full Text] [Related]
34. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
Liu J; Zhang L; Zhang X; Xing X
J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
[TBL] [Abstract][Full Text] [Related]
35. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G
Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
[TBL] [Abstract][Full Text] [Related]
36. Combination of Ad-sTRAIL with the chemotherapeutic drug cisplatin synergistically enhances their pro-apoptotic ability in human breast cancer cells.
Liu X; Wang J; Wang H; Liu S; Liang Y; Lv Z; Zhou Q; Ding W
Oncol Rep; 2013 Oct; 30(4):1913-9. PubMed ID: 23912708
[TBL] [Abstract][Full Text] [Related]
37. Characterization of a novel anti-DR5 monoclonal antibody WD1 with the potential to induce tumor cell apoptosis.
Wang J; Lin Z; Qiao CX; Lv M; Yu M; Xiao H; Wang Q; Wang L; Feng J; Shen B; Ma Y; Li Y
Cell Mol Immunol; 2008 Feb; 5(1):55-60. PubMed ID: 18318995
[TBL] [Abstract][Full Text] [Related]
38. Enhancement of Apo2L/TRAIL-mediated cytotoxicity in esophageal cancer cells by cisplatin.
Tsai WS; Yeow WS; Chua A; Reddy RM; Nguyen DM; Schrump DS; Nguyen DM
Mol Cancer Ther; 2006 Dec; 5(12):2977-90. PubMed ID: 17172403
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model.
Estes JM; Oliver PG; Straughn JM; Zhou T; Wang W; Grizzle WE; Alvarez RD; Stockard CR; LoBuglio AF; Buchsbaum DJ
Gynecol Oncol; 2007 May; 105(2):291-8. PubMed ID: 17303227
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of IGF-1R-dependent PI3K activation sensitizes colon cancer cells specifically to DR5-mediated apoptosis but not to rhTRAIL.
Pennarun B; Kleibeuker JH; Oenema T; Stegehuis JH; de Vries EG; de Jong S
Anal Cell Pathol (Amst); 2010; 33(5):229-44. PubMed ID: 20978316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
